The recently approved programmed death 1 (PD-1) inhibition therapy has clearly improved survival outcomes for HCC with a tolerable safety profile when combined with the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab4. Here, VEGFA is linked to hepatocellular carcinoma.